Pharmacokinetics And Bioavailability Of Tildipirosin Following Intravenous And Subcutaneous Administration In Sheep

Tildipirosin is a semi-synthetic macrolide antibiotic commonly used in cattle and swine to treat bacterial pneumonia. The objective of this study was to investigate the pharmacokinetic profile of tildipirosin after a single intravenous (i.v.) and subcutaneous (s.c.) administration in healthy lambs. Eighteen lambs were randomly divided into three groups (n = 6 each). Lambs received a single s.c. dose of tildipirosin at 4 and 6 mg/kg b.w. in group 1 and 2, respectively. Lambs in group 3 received a single i.v. dose of tildipirosin at 4 mg/kg b.w. Blood samples were collected at 0, 0.5, 0.75, 1.5, 2, 3, 4, 6, 8, 10, 24, 36, 48 hr, and every 24 hr to day 21, and thereafter at day 28 posttildipirosin administration. The plasma concentrations of tildipirosin were determined using high-performance liquid chromatography with tandem mass spectrometry detection (LC forward slash MS forward slash MS). All lambs appeared to tolerate both the intravenous and subcutaneous injection of tildipirosin. Following i.v. administration, the elimination half-life (T-1/2), mean residence time (MRT), volume of distribution (Vd/F), and total body clearance (Cl/F) were 119.6 +/- 9.0 hr, 281.9 +/- 25.7 hr, 521.1 +/- 107.2 L, and 2.9 +/- 0.5 L/hr, respectively. No significant differences inC(max)(657.0 +/- 142.8 and 754.6 +/- 227.1 ng/ml),T-max(1.21 +/- 0.38 and 1.35 +/- 0.44 hr), T-1/2(144 +/- 17.5, 156.5 +/- 33.4 hr), and MRT (262.0 +/- 30.2 and 250.6 +/- 54.5 hr) were found in tildipirosin after s.c. dosing at 4 and 6 mg/kg b.w., respectively. The absolute bioavailability (F) of tildipirosin was 71.5% and 75.3% after s.c. administration of 4 and 6 mg/kg b.w., respectively. In conclusion, tildipirosin was rapidly absorbed and slowly eliminated after a single s.c. administration in healthy lambs. Tildipirosin could be used for the treatment and prevention of respiratory bacterial infections in sheep. However, further in vitro and in vivo studies to determine the efficacy and safety are warranted. To our knowledge, this is the first study to determine the tildipirosin pharmacokinetic parameters in sheep plasma.